Skip to main content

Table 2 Adjusted hazards ratios and 95% confidence intervals for the risk of ischemic stroke and hemorrhagic stroke across terminal nodes in the Kailuan I participants with low-density lipoprotein cholesterol concentrations < 70 mg/dL

From: The risk of ischemic stroke and hemorrhagic stroke in Chinese adults with low-density lipoprotein cholesterol concentrations < 70 mg/dL

  Ischemic stroke, HR (95%CI)
Node1 Node2 Node3 Node4 Node5 Node6 Node7 Node8 Node9
Case/person-years 15/28,515 37/15,483 78/14,743 60/10,818 8/1026 119/12,021 10/547 53/2553 8/143
LDL-C ± SD, mg/dL 56.8 ± 10.9 57.3 ± 10.8 64.6 ± 3.03 57.7 ± 8.76 55.6 ± 11.9 50.1 ± 6.48 19.2 ± 8.90 20.3 ± 8.53 20.6 ± 9.63
Multivariate modela 1.00 (reference) 3.73 (2.01, 6.92) 7.07 (3.98, 12.6) 7.38 (4.05, 13.4) 8.44 (3.04, 23.4) 13.0 (7.41, 22.7) 20.8 (7.86, 54.8) 23.1 (12.4, 43.1) 76.3 (30.2, 192.7)
Excluding eGFR < 60 ml/min/1.73 m2 1.00 (reference) 3.60 (1.94, 6.70) 6.06 (3.37, 10.9) 7.10 (3.85, 13.1) 8.86 (3.19, 24.6) 12.8 (7.30, 22.4) 18.9 (6.69, 53.4) 24.6 (13.1, 46.2) 62.2 (23.3, 166.3)
Excluding Framingham risk score > 30% 1.00 (reference) 3.82 (2.02, 7.23) 6.41 (3.38, 12.1) 6.71 (3.29, 13.7) 10.4 (3.74, 29.2) 12.3 (6.74, 22.4) 24.2 (6.74, 86.6) 23.3 (11.2, 48.1) 76.8 (24.7, 238.3)
Excluding BMI < 18.5 kg/m2 1.00 (reference) 3.75 (2.02, 6.94) 7.01 (3.94, 12.5) 7.51 (4.12, 13.7) 8.37 (3.02, 23.2) 13.0 (7.45, 22.8) 21.9 (8.29, 57.9) 23.1 (12.4, 43.1) 74.5 (29.5, 188.2)
Excluding blood pressure-lowering drugs 1.00 (reference) 3.48 (1.85, 6.56) 6.49 (3.50, 12.0) 7.24 (3.88, 13.5) 9.26 (3.32, 25.8) 11.0 (6.10, 19.8) 22.0 (8.24, 59.0) 22.3 (11.5, 43.2) 52.1 (16.8, 161.5)
Excluding glucose-lowering drugs 1.00 (reference) 3.69 (1.98, 6.87) 6.92 (3.87, 12.4) 7.81 (4.27, 14.3) 9.35 (3.36, 26.0) 13.1 (7.49, 23.0) 18.0 (6.39, 50.7) 21.8 (11.6, 40.9) 63.1 (23.7, 168.0)
  Hemorrhagic stroke, HR (95%CI)
Node1 Node2 Node3 Node4 Node5 Node6
Case/person-years 13/41,704 13/4435 19/10,553 75/27,377 12/2102 13/739
LDL-C ± SD, mg/dL 59.3 ± 7.25 28.9 ± 9.75 58.8 ± 7.51 57.8 ± 8.82 19.9 ± 8.60 20.2 ± 8.03
Multivariate modela 1.00 (reference) 4.40 (2.07, 9.33) 6.59 (3.55, 12.2) 5.41 (2.22, 13.2) 9.74 (3.84, 24.7) 41.7 (17.2, 101.6)
Excluding eGFR < 60 ml/min/1.73 m2 1.00 (reference) 4.58 (2.13, 9.85) 6.55 (3.52, 12.2) 4.68 (1.84, 11.9) 9.98 (3.78, 26.4) 37.5 (15.3, 91.6)
Excluding Framingham risk score > 30% 1.00 (reference) 5.09 (2.02, 12.8) 5.01 (2.51, 9.99) 4.11 (1.52, 11.1) 10.7 (3.25, 35.2) 21.3 (6.86, 65.9)
Excluding BMI < 18.5 kg/m2 1.00 (reference) 4.52 (2.13, 9.59) 6.46 (3.48, 12.0) 4.85 (1.91, 12.3) 9.71 (3.82, 24.7) 42.6 (17.4, 104.2)
Excluding blood pressure-lowering drugs 1.00 (reference) 3.55 (1.57, 8.03) 5.39 (2.78, 10.4) 5.03 (2.05, 12.4) 7.73 (2.60, 23.1) 34.0 (12.8, 89.9)
Excluding glucose-lowering drugs 1.00 (reference) 4.56 (2.14, 9.69) 6.42 (3.44, 12.0) 5.52 (2.26, 13.5) 10.2 (4.00, 25.8) 38.1 (15.2, 95.4)
  1. Abbreviations: HR, hazard ratio; CI, confidence interval; LDL-C, low-density lipoprotein cholesterol; SD, standard deviation; eGFR, estimated glomerular filtration rate; BMI, body mass index
  2. aAll models were adjusted for sex (men or women), age (year), physical activity (inactive, moderately active, or vigorously active), smoking and drinking status (never, former, occasional or daily), blood pressure status during follow-up (well-controlled or poorly controlled), blood glucose status during follow-up (well-controlled or poorly controlled), body mass index (kg/m2), urine protein (negative, trace, +, ++, or +++), heart rate (bpm), triglyceride (mg/dL), high-density lipoprotein cholesterol (mg/dL), low-density lipoprotein cholesterol (mg/dL), estimated glomerular filtration rate (ml/min/1.73 m2), and high-sensitivity C-reactive protein (mg/L)